Trogarzo® (ibalizumab)
Multidrug‑resistant HIV‑1 infection
CommercialActive
Key Facts
About TaiMed Biologics
TaiMed Biologics combines CD4‑targeted biologics with CDMO services to address HIV and autoimmune markets.
View full company profileMultidrug‑resistant HIV‑1 infection
TaiMed Biologics combines CD4‑targeted biologics with CDMO services to address HIV and autoimmune markets.
View full company profile